BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
41.86
-0.59 (-1.39%)
At close: 4:00PM EDT

41.75 -0.11 (-0.26%)
After hours: 6:20PM EDT

Stock chart is not supported by your current browser
Previous Close42.45
Open42.57
Bid41.87 x 2200
Ask42.08 x 2200
Day's Range41.83 - 42.68
52 Week Range31.56 - 43.66
Volume4,395,309
Avg. Volume8,339,848
Market Cap58.213B
Beta (3Y Monthly)0.71
PE Ratio (TTM)32.70
EPS (TTM)1.28
Earnings DateJul 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.55
Trade prices are not sourced from all markets
  • Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD
    Zacks5 days ago

    Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD

    The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.

  • The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices

    The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices

  • Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific
    Zacks7 days ago

    Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific

    Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific

  • Boston Scientific's Global Growth Robust Amid Currency Woe
    Zacks7 days ago

    Boston Scientific's Global Growth Robust Amid Currency Woe

    Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Boston Scientific Corp.

    Boston Scientific Corp NYSE:BSXView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $3.26 billion over the last one-month into ETFs that hold BSX are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BSX credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout
    Zacks9 days ago

    Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

    The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

  • Here's Why I Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today
    Simply Wall St.9 days ago

    Here's Why I Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

  • Edwards Lifesciences Recalls Heart Device on Balloon Rupture
    Zacks12 days ago

    Edwards Lifesciences Recalls Heart Device on Balloon Rupture

    Shares of Edwards Lifesciences (EW) decline post product recall news.

  • 3 Healthcare Stocks Ready to Grow
    TipRanks13 days ago

    3 Healthcare Stocks Ready to Grow

    2019 has been a rocky year for the healthcare industry. The general healthcare market sell-off combined with criticism over high costs poses a cause for concern. Despite the lackluster performance of many healthcare stocks so far in 2019, there are a few standouts with long-term growth potential. Using data from TipRanks, we’ve narrowed down three stocks in the healthcare space that analysts believe are well positioned for future growth. Boston Scientific Corporation (BSX)Unlike other stocks in the healthcare industry, Boston Scientific shares saw significant growth over the last year. The medical equipment manufacturer’s stock increased 22.5% while the industry as a whole saw only a 4% increase. In the quarter ending March 31, the company reported calendar year increases in revenue and net profit. Revenue was up from $2.38 billion to $2.49 billion while net profit increased from $298 million to $424 million.Boston Scientific’s long-term growth plan, which includes projections of double digit adjusted EPS growth through 2020, gives analysts reason to believe the company will continue to outperform. Raj Denhoy, a top analyst from Jeffries, raised his price target from $44 to $48 stating that the company’s projections from their investor meeting were “another positive look at a story that has been in sharp ascendancy for the last five years.” He added that the projections are even somewhat conservative given the company’s stability and the addition of new products in the next few quarters. Another five-star analyst, Matt Miksi of Credit Suisse, explained that he is unsurprised by Boston’s success when discussing the company’s sale of various products from their portfolio to Varian for $90 million. He maintained the stock’s Outperform rating and $45.00 price target, indicating a 5.56% upside. The Street’s outlook on the stock is bullish, with 10 analysts from TipRanks giving a buy rating vs just 1 hold over the last three months. The stock boasts a ‘Strong Buy’ analyst consensus and an average price target of $45.63, suggesting a 7.04% upside. View BSX Price Target & Analyst Rating Details Invitae Corporation (NVTA)Invitae is an innovative biotech company in the genetic testing segment of the market whose goal is to make genetic screenings more affordable and accessible. Five-star financial blogger, Todd Campbell, notes that the company cut the cost of goods sold by upwards of 20% over the last year as well as reported year-over-year sales of $148 million, a 117% increase. Management is projecting sales of $220 million in 2019 and a test volume of 500,000.  Additionally, the company announced on June 17 that they are set to acquire Singular Bio. “The acquisition of Singular Bio gives Invitae a critical technology that can turn the NIPS business into a 50% gross margin performer once fully integrated into the firm’s process, and if you broke out Invitae's cancer business, it turned a profit as a standalone business as of Q1 of this year,” stated Sean George, the company’s CEO. Five-star rated Cowen & Co. analyst, Doug Schenkel, is confident in the stocks ability to grow, reiterating his Outperform rating and $30.00 price target. He believes Singular Bio’s “flexible, quick, and less expensive technology will give Invitae a competitive advantage over other companies with sequencing-based and microarray-based approaches for some applications including NIPS/NIPT.”The consensus among analysts is that the stock is a ‘Strong Buy’, with an average price target of $30.00, suggesting a 23.61% upside. View NVTA Price Target & Analyst Rating Details Teladoc Health, Inc. (TDOC)The last stock on our list doesn’t appear to be slowing down any time soon. Teladoc meets the growing demand for healthcare access in a cost-effective way by providing virtual medical care through telephone and videoconferencing technology. Share prices surged by 35.73% year-to-date. Management is confident that this growth will continue throughout the rest of the year. Based on Teladoc’s recent acquisitions as well as their competitive advantage within this segment of the healthcare sector, management is anticipating 37% revenue growth. In the most recent quarter, the company reported 29% organic growth with 1,063,000 total visits. Richard Close, an analyst at Canaccord Genuity, believes that the telemedicine company’s “penetration into its existing client base will allow it to generate robust organic growth.” He maintains his buy rating on the stock and price target of $95.00 (41.20% upside).  Five-star Piper Jaffray analyst, Sean Wieland, remains bullish on the stock. He explained that he views the completion of their CFO search and an impending United deal as “two important catalysts and remains a buyer of the stock in front of them.” He reiterated his Overweight rating and price target of $86.00, suggesting a 27.82% upside.While the on-demand remote medical care provider isn’t profitable yet, analysts believe in Teladoc’s growth potential. The stock has a ‘Strong Buy’ analyst consensus, with 12 out of 13 analysts on TipRanks giving a buy rating. The average price target of $79.83 shows that analysts believe the stock price could increase by 18.65%. View TDOC Price Target & Analyst Rating DetailsFind your own best investment with TipRanks’ Analysts’ Top Stocks page.

  • Stock Market News for Jul 3, 2019
    Zacks14 days ago

    Stock Market News for Jul 3, 2019

    Wall Street registered decent gains on Tuesday.

  • Varian to Acquire Boston Scientific's Embolic Bead Products
    Zacks14 days ago

    Varian to Acquire Boston Scientific's Embolic Bead Products

    Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.

  • Analysts bullish on Boston Scientific's plans for 75 new products by 2022
    American City Business Journals14 days ago

    Analysts bullish on Boston Scientific's plans for 75 new products by 2022

    Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.

  • Benzinga15 days ago

    Varian Will Acquire Embolic Bead Asset From Boston Scientific

    Varian Medical Systems (NYSE: VAR ) will acquire Boston Scientific’s (NYSE: BSX ) portfolio of drug-loadable microsphere and bland embolic bead products. Terms of the transaction were not disclosed. Boston ...

  • Insider Monkey15 days ago

    Marshall Wace’s Return, AUM, and Holdings (Part II)

    Read the beginning of this article here. At the end of March 2019, Marshall Wace held the most valuable position in Zoetis Inc. (NYSE:ZTS), the biggest producer of vaccinations and medicine for livestock and pets that was once a part of the world’s biggest drug maker, Pfizer. The company has a market cap of $54.81 […]

  • Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results
    PR Newswire16 days ago

    Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results

    MARLBOROUGH, Mass. , July 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ...

  • GuruFocus.com19 days ago

    Boston Scientific May Be Too Rich for Johnson & Johnson

    Market value of medical device maker up nearly 30% since December

  • Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group
    PR Newswire19 days ago

    Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group

    ARTARMON, Australia , June 28, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that it has secured $75 million in equity financing from Boston Scientific Corporation ...

  • Why This Medtech Stock Could Top Its Own Bullish 3-Year Outlook
    Investor's Business Daily20 days ago

    Why This Medtech Stock Could Top Its Own Bullish 3-Year Outlook

    Boston Scientific will likely top its own three-year guidance for a 6%-9% compound annual growth rate, analysts said Thursday as the medical technology company expands its heart devices.

  • Boston Scientific Strong on Growth Goals and Future Launches
    Zacks20 days ago

    Boston Scientific Strong on Growth Goals and Future Launches

    This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.

  • Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day
    PR Newswire21 days ago

    Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day

    MARLBOROUGH, Mass., June 26, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is presenting plans for its product pipeline and strategic investments to enable improved clinical and economic outcomes, sustain category leadership in served markets and expand into high-growth, adjacent markets to deliver strong financial performance across the company's MedSurg, Rhythm and Neuro, and Cardiovascular segments. "This is an exciting time for Boston Scientific to help more patients live better and longer lives through the benefits provided by our current medical devices and treatment therapies, while we invest in and develop a robust, long-term pipeline of future technologies," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.

  • CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?
    Zacks22 days ago

    CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?

    While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.

  • Moody's23 days ago

    Boston Scientific Corporation -- Moody's announces completion of a periodic review of ratings of Boston Scientific Corporation

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Boston Scientific Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • ACCESSWIRE23 days ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX, HRTX and BOX

    CEDARHURST, NEW YORK / ACCESSWIRE / June 24, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • GlobeNewswire23 days ago

    DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE: BSX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

  • ACCESSWIRE23 days ago

    FINAL DEADLINE ALERT - Boston Scientific Corporation (BSX) Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: June 24, 2019

    NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between February 26, 2015, and April 16, 2019, both dates inclusive. Boston Scientific was founded in 1979 and is headquartered in Marlborough, Massachusetts. The Company develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.